Synopsis
This one-day symposium will explore some of the latest approaches in drug discovery and review the hottest topics in medicinal chemistry being used to discover the drugs of tomorrow. Bringing together a wide range of speakers, the day will cover a range of approaches and techniques within drug discovery, including bifunctional modalities, ML-enabled drug discovery, and novel hit-finding strategies.
Attendees
This conference is for academic and industrial medicinal chemists at all career points, with an interest in applying innovative and modern strategies to the early stages of drug discovery.
Programme
Wednesday 12 November 2025
- 10.00
- Registration and refreshments
Session 1
- 10.35
Will Pitt, Evotec
- 11.15
Speaker to be confirmed, Avacta Therapeutics
- 11.55
- Poster flash presentations
- 12.15
- Lunch and poster session
Session 2
- 13.30
- PINADs - reprogramming small molecules into targeted RNA degraders
Sigitas Mikutis, University of Cambridge
- 14.10
Darren Poole, GSK
- 14.50
- Refreshment break
Session 3
- 15.20
Will Farnaby, University of Dundee/Centre for targeted protein degradation
- 16.00
Rebecca Paul, Isomorphic Labs
- 16.40
- Concluding remarks
- 16.50
- Networking reception
SCI’s Young Chemists’ Panel are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with inclusivity of gender and ethnicity. Attendees from all backgrounds and ages are welcome.
Sponsorship information
Please see the sponsorship pack and email conferences@soci.org to let us know which package you are interested in.
Accessibility Grants
SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.
Venue and Contact
Booking Process/Deadlines
Booking terms and conditions
CPD Info
All delegates attending this meeting are able to claim CPD points.

Organising committee
Sophie Bertrand, GSK
Rob Griffiths, Nxera Pharma
Giorgia Kidd, University of Dundee
Kim Roper, University of Birmingham